Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Conditions

• Non-Small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ivonescimab Injection — BIOLOGICAL
  Subject will receive ivonescimab as an IV injection
• Pembrolizumab Injection — BIOLOGICAL
  Subject will receive Pembrolizumab as an IV injection

Study Details

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Key Dates

First listed

Jan 10, 2025

Start date

Feb 27, 2025

Status verified

Aug 2026

Primary completion

Apr 30, 2028

Completion

Jun 30, 2029

Study Design

Enrollment

780 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A - Ivonescimab
  Subject will receive ivonescimab as an IV injection
• Active Comparator: Arm B - Pembrolizumab
  Subject will receive pembrolizumab as an IV injection

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: Up to approximately 36 months ]

Central Contacts

• Summit Clinical Trial Information
  1-833-256-0522
  [email protected]

Locations (94)

Find similar trials in Chandler, AZ

Related Studies

• Harvesting Cells for Experimental Cancer Treatments
  Enrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
  PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
  PHASE3 · Recruiting · University of Texas Southwestern Medical Center · Savannah, Georgia